PLAUDIT: A Study of APL-2 in Autoimmune Hemolytic Anemia
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

PLAUDIT: A Study of APL-2 in Autoimmune Hemolytic Anemia

Sponsor: Apellis Pharmaceuticals, Inc.

Protocol: APL2-CP-AIHA-208. An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients with Warm Antibody Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD).